ATE141162T1 - Antineoplastische lösung und verfahren zur behandlung von neoplasmen - Google Patents

Antineoplastische lösung und verfahren zur behandlung von neoplasmen

Info

Publication number
ATE141162T1
ATE141162T1 AT90907638T AT90907638T ATE141162T1 AT E141162 T1 ATE141162 T1 AT E141162T1 AT 90907638 T AT90907638 T AT 90907638T AT 90907638 T AT90907638 T AT 90907638T AT E141162 T1 ATE141162 T1 AT E141162T1
Authority
AT
Austria
Prior art keywords
vehicle
agent
tumor
tissue
antineoplastic
Prior art date
Application number
AT90907638T
Other languages
English (en)
Inventor
Dennis D Pietronigro
Original Assignee
Dennis D Pietronigro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dennis D Pietronigro filed Critical Dennis D Pietronigro
Application granted granted Critical
Publication of ATE141162T1 publication Critical patent/ATE141162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT90907638T 1989-05-09 1990-05-08 Antineoplastische lösung und verfahren zur behandlung von neoplasmen ATE141162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/349,410 US5051257A (en) 1989-05-09 1989-05-09 Antineoplastic solution and method for treating neoplasms

Publications (1)

Publication Number Publication Date
ATE141162T1 true ATE141162T1 (de) 1996-08-15

Family

ID=23372285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90907638T ATE141162T1 (de) 1989-05-09 1990-05-08 Antineoplastische lösung und verfahren zur behandlung von neoplasmen

Country Status (9)

Country Link
US (1) US5051257A (de)
EP (1) EP0471751B1 (de)
JP (1) JP3101702B2 (de)
AT (1) ATE141162T1 (de)
AU (1) AU640657B2 (de)
CA (1) CA2055493C (de)
DE (1) DE69028102T2 (de)
ES (1) ES2090131T3 (de)
WO (1) WO1990013289A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5519221A (en) * 1992-01-22 1996-05-21 Ansel M. Schwartz Dedicated apparatus and method for emission mammography
US6229145B1 (en) * 1992-01-22 2001-05-08 Pem Technologies, Inc. Dedicated apparatus and method emission mammography
SE9202128D0 (sv) * 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
CA2180260A1 (en) * 1993-12-29 1995-07-06 Dennis M. Brown Methods and compositions for the treatment of a host with a cellular proliferative disease
US6322815B1 (en) 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
PT788351E (pt) * 1994-11-10 2003-06-30 Univ Kentucky Res Foundation T Dispositivo implantavel recarregavel de libertacaocontrolada para administrar medicamentos direc tamente numa porcao interna do corpo
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
WO1999033492A1 (en) * 1997-12-31 1999-07-08 Direct Therapeutics, Inc. Method for tissue perfusion
US6753005B1 (en) 1997-12-31 2004-06-22 Direct Therapeutics, Inc. Method for tissue perfusion
US20050255039A1 (en) * 1998-06-26 2005-11-17 Pro Surg, Inc., A California Corporation Gel injection treatment of breast, fibroids & endometrial ablation
SE9803482D0 (sv) 1998-10-13 1998-10-13 Anders Holmberg Ion exchange tumor targeting (IETT)
ATE300957T1 (de) 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
WO2004006976A1 (en) * 2002-07-12 2004-01-22 Cook Incorporated Coated medical device
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
RU2250087C1 (ru) * 2004-06-16 2005-04-20 Институт Мозга Человека Российской Академии Наук (Имч Ран) Способ лечения глиальных новообразований мозга
WO2007085026A2 (en) * 2006-01-20 2007-07-26 The Board Of Regents Of The University Of Texas System Compositions and methods for the direct therapy of tumors
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010033248A2 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Neutral nanotransporters
JP5670335B2 (ja) * 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8541748B2 (en) * 2009-06-29 2013-09-24 General Electric Company System and method for performing nuclear mammography imaging
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP2575763A2 (de) * 2010-06-04 2013-04-10 North-West University Injizierbare formulierung eines hemmers der reversen transkriptase zur behandlung von krebs
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
JP2018531037A (ja) 2015-10-19 2018-10-25 アールエックスアイ ファーマシューティカルズ コーポレーション 長い非コードｒｎａを標的とする減少したサイズの自己送達型核酸化合物
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
MX2022010387A (es) * 2020-04-13 2022-09-05 US Nano Food & Drug INC Formulacion basica para inyeccion quimioterapeutica intratumoral.
CA3182871A1 (en) * 2020-06-15 2021-12-23 Kortuc Inc. Sensitizer for cancer treatment
US11459567B2 (en) 2020-06-24 2022-10-04 Patricia Virginia Elizalde Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4558690A (en) * 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
EP0086627B1 (de) * 1982-02-12 1985-08-28 Unitika Ltd. Antikrebsmittel
DE3513938A1 (de) * 1985-04-18 1986-10-23 Merck Patent Gmbh, 6100 Darmstadt Cytostatikahaltiges pharmakadepot
DE3772482D1 (de) * 1986-07-11 1991-10-02 Asta Pharma Ag Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung.
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas

Also Published As

Publication number Publication date
EP0471751A1 (de) 1992-02-26
JP3101702B2 (ja) 2000-10-23
AU5636090A (en) 1990-11-29
EP0471751A4 (en) 1992-07-22
ES2090131T3 (es) 1996-10-16
DE69028102T2 (de) 1997-01-23
CA2055493C (en) 2001-04-17
AU640657B2 (en) 1993-09-02
EP0471751B1 (de) 1996-08-14
JPH04506659A (ja) 1992-11-19
WO1990013289A1 (en) 1990-11-15
CA2055493A1 (en) 1990-11-10
US5051257A (en) 1991-09-24
DE69028102D1 (de) 1996-09-19

Similar Documents

Publication Publication Date Title
ATE141162T1 (de) Antineoplastische lösung und verfahren zur behandlung von neoplasmen
ID25622A (id) Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol
NZ334190A (en) Method for improved selectivity in photo-activation of molecular agents
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
DE69127175D1 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
ES2063912T3 (es) Composiciones inmunogenicas frente a peptidos de gastrina.
SE8803087L (sv) Ett nytt saett foer behandling av erektil dysfunktion
ATE242635T1 (de) Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
DE3767992D1 (de) Elektrochemisches verfahren fuer die behandlung von kohlenstoffasern und nach diesem verfahren behandelte fasern.
AR005962A1 (es) Aparato y composicion para la limpieza de una superficie
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2&#39;-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE349999T1 (de) Zweikomponenten-mittel mit zeitlichem ph- gradienten und verfahren zur behandlung von haaren
DE69526884D1 (de) Kombinationen von vasoaktiven Stoffen mit Fettsäuren zur Verhütung von Haarausfall
BR9808221A (pt) Método de tratamento de tumor.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE69431064D1 (de) Nassbehandlung von leder und pelzen
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE110961T1 (de) Behandlung von beatmungsabhängigkeit mit wachstumshormon.
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee